Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cellular Immune Responses in Triple-negative Breast Cancer - High Throughput Immunogenetic Studies

NCT06646263 is registered in ClinicalTrials.gov with Institute of Applied Biosciences as lead sponsor.

NCT NCT06646263
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06646263 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cellular Immune Responses in Triple-negative Breast Cancer - High Throughput Immunogenetic Studies
Lead sponsor
Institute of Applied Biosciences
Phase
Observational
Overall status
Enrolling by invitation
Start date
March 1, 2024
Completion date
April 30, 2028
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer